Skip to content

Three male doctors in white coats in a black and white photo taken in 1892
Dr. William Coley (center), public domain photo from https://commons.wikimedia.org/wiki/File:William_Coley_1892.jpg

May is Melanoma Awareness Month, which serves as an annual reminder to visit a dermatologist regularly for a skin check. Melanoma affects every skin tone. Visit Himmelfarb's collection, Diversity in Dermatology, to explore our library resources on this topic.

This year, let’s go back in time to learn about the origin of one tremendous contemporary advance in the treatment of malignant melanoma -- immunotherapy -- and learn about a new development coming for patients diagnosed with melanoma.

Dr. William Coley (1862-1936) was a bone surgeon and cancer researcher who spent his career at the New York Cancer Hospital. At the time, cancers were commonly treated with amputation. Coley’s young patient, 17 year old Elizabeth Dashiell, presented with an aggressive sarcoma in her hand. Despite an amputation, her cancer had metastasized and she died ten weeks later. Coley began to comb through hospital records, and found a patient who had had four recurrences of an inoperable sarcoma, whose disease had gone into remission when he developed a superficial streptococcal infection of the skin. Coley managed to locate the patient, who did not present with any clinical evidence of malignancy. He also found a number of observational publications connecting this particular skin infection with positive outcomes for sarcoma patients.

Cover of a medical monograph from 1914
The Treatment of Malignant Inoperable Tumors, by William B. Coley, MD (1914)

Coley began intentionally inducing this skin infection in his cancer patients, despite the fact that antibiotics were not yet available to help control infections. His practice is of course shocking and unethical in the light of our contemporary understanding of medical ethics. Additionally, the specific infection, erysipelas, was difficult to induce in patients, some of whom never developed the infection, and some of whom were injected repeatedly in the attempt to induce it. Having achieved some results with his initial attempts, Coley began using a heat-killed version of the infection, combined with one other toxin (which is known to us today as Serratia marcescens) to increase the virulence, and in turn, patients’ immune responses. This combination came to be known as “Coley’s toxins.” A summary of the patients treated with Coley’s toxins prior to 1940 shows that 22 soft-tissue sarcoma patients and 8 lymphoma patients were found to be free of clinical evidence of disease for a period of at least 20 years. (Starnes, 1992). Results for other types of cancers varied, but were not nearly as dramatic. You can read Coley’s 1914 report on his treatment of patients with toxins in its entirety online.

The concept of inducing an immune response in patients to address malignancies also underlies the pioneering work done by contemporary researcher James Allison, for which he shared the 2018 Nobel prize with Tasuku Honjo, for their work on immunotherapy. Allison’s work is chronicled in the documentary Breakthrough, which is available to stream on a number of platforms. Immune checkpoint therapy stimulates the patient’s immune system by blocking inhibitory checkpoints, in order to enable T cells to attack the tumor. Currently, immune checkpoint inhibitors which target the molecules CTLA4, PD-1, and PD-L1 are approved. The very first immune checkpoint therapy, ipilimumab, was approved in 2011 for the treatment of melanoma; since then, seven additional immune checkpoint inhibitors have been approved for use in the treatment of an ever-increasing number of cancers.

Research is ongoing towards the development of melanoma vaccines, which also build on the basis of activating patients’ own immune systems. The April 2024 issue of Cancer Research contains a brief comment on the growing body of evidence for vaccines tailored to specific tumor mutations, noting that progress has accelerated and increased during the past five years. (Fritsch & Ott, 2024) 

While the ultimate goal is to prevent patients from developing melanoma in the first place, the results of research are leading to exciting and unprecedented outcomes for patients who have the disease. Dr. Coley’s early work with the immune system of cancer patients reminds us that pioneering ideas may come before their time and before the technology exists to support them, but may nonetheless lead to unimaginable and positive outcomes centuries later.

References

Coley, W. B. The Treatment of Malignant Inoperable Tumors with the Mixed Toxins of Erysipelas and Bacillus Prodigiosus : With a Brief Report of 80 Cases Successfully Treated with the Toxins from 1893 to 1914 / by William B. Coley. M. Weissenbruch, 1914; 1914.

Fritsch, E. F., & Ott, P. A. (2024). Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans. Cancer research, 84(7), 953–955. https://doi.org/10.1158/0008-5472.CAN-24-0565

Starnes C. O. (1992). Coley's toxins in perspective. Nature, 357(6373), 11–12. https://doi.org/10.1038/357011a0

Portrait of Beethoven by Scott Gentling
Scott Gentling (1942-2011).Beethoven.[undated].Graphite on paper.Amon Carter Museum of American Art, Fort Worth, Texas.2018.70, CC BY-SA 4.0, via Wikimedia Commons

Beethoven, one of the great musical geniuses of the 19th century, was deaf when he wrote some of his best known works. He had progressive hearing loss starting in his 20’s and was functionally deaf during his late period when he wrote his most expressive and innovative sonatas, string quartets, and the Ninth Symphony (Ode to Joy). Beethoven also suffered from gastrointestinal symptoms most of his adult life and died of liver failure. In 1802, he requested that his medical conditions be disclosed to the public after his death in a letter to his brothers known as the Heiligenstadt Testament.

Historians and musicologists have speculated if he had a heritable disorder or infectious disease that contributed to his hearing loss and death. Alcoholism was suspected as a factor in his liver disease. There was a family history of alcohol dependence and some of his associates claimed he drank heavily, though others said he did not drink more than was typical at that time.

Recent advances in ancient DNA methods presented an opportunity to learn more about Beethoven’s medical conditions. A team of 32 international researchers used eight surviving locks of Beethoven’s hair for their analysis. Several locks were taken by friends when Beethoven died in 1827 and others were given to friends and associates while he was alive.  Over the years they were sold and passed down to others and the provenance of some were questionable. The locks were analyzed in this new study to determine their authenticity, using a novel geo-genetic triangulation technique. Additionally, the researchers “analyzed Beethoven’s genome for genetic causes of and risk for somatic disorders in addition to metagenomic screening for evidence of infections, followed by targeted DNA capture.” (Begg, et al, 2023)

Five of the locks were determined to originate from a single individual or monozygotic twins and had damage patterns that authenticated them for early 19th century origin. A non-matching lock called the Hiller lock was used in previous genetic and forensic testing featured in the book and movie, Beethoven’s Hair. It was found to be from a woman, invalidating results indicating lead poisoning as a contributor to Beethoven’s hearing loss and other maladies.

Analysis on the Y chromosome revealed a surprise finding. Five living men from the Beethoven patrilineage had a common ancestor in Aert van Beethoven (1535-1609). But their Y chromosomes did not match with any of the five authenticated Beethoven hair samples. The researchers conclude that there was at least one extra pair paternity event in Beethoven’s ancestry. Further analysis of descendants of Beethoven’s brother Karl leaves open the possibility that the two may have been half brothers.

Beethoven’s GI symptoms were consistent with Crohn’s disease or ulcerative colitis. His hearing loss could have been associated. Other possible related causes for the hearing loss were otosclerosis, sarcoidosis or systemic lupus erythematosus. A genome wide association study eliminated most of these as possibilities, except for lupus where there was some elevated polygenic risk. 

Celiac disease and lactose intolerance were both eliminated as possible causes of his gastrointestinal symptoms through testing for associated alleles. He actually had some elevated genetic protections against irritable bowel syndrome, making it also unlikely. 

They analyzed 55 genes where variants could cause monogenic post-lingual hearing loss and 209 related to pre-lingual hearing loss. There were no positive findings.

In summary, we could not reliably evaluate most hypothesized multifactorial causes of Beethoven’s hearing loss, nor did we identify a monogenic origin.”

(Begg, et al, 2023)

Beethoven’s polygenic risk for liver cirrhosis was found to be elevated in his PNPLA3 gene and his HFE gene. This combined with heavy drinking could have caused his liver failure. Additionally, hepatitis B DNA was found in the Stumpff Lock hair which was the best preserved sample. Researchers could not tell how long he’d had the hepatitis B infection. The positive lock was taken at his death and represented the final months of his life. Tristan Begg, the lead author of the study, wrote more about the possible role of hepatitis B in Beethoven’s liver failure on William Meredith’s blog. Meredith is a Beethoven scholar who participated in the genome study.

Though not addressed directly in the paper, the study brings to an end the theory that Beethoven was black. Noting the similarities in their appearance, the bi-racial composer Samuel Coleridge-Taylor was the first to raise the possibility. Many contemporaries of Beethoven described him as dark, brown or ruddy in complexion and noted his broad, rounded nose which can be seen in his life mask taken in 1812. The idea has persisted since Coleridge-Taylor introduced it, and was repeated by Malcolm X and a 1969 Rolling Stones article titled “Beethoven was black and proud!” More recently it was the subject of scholarly articles and even a Twitter meme. This genomic analysis confirms that Beethoven’s ancestry was greater than 99% European, with the strongest autosomal match with present day North Rhine-Westphalia in Germany.

Although there was no definitive finding on Beethoven’s hearing loss, there was plenty to advance the existing knowledge base and establish leads for future research. The study demonstrates how much can be learned from a few strands of centuries old hair through new genetic analysis tools.

References

Begg TJA, Schmidt A, Kocher A, et al. Genomic analyses of hair from Ludwig van Beethoven. Curr Biol. 2023 Apr 24;33(8):1431-1447.e22. doi: 10.1016/j.cub.2023.02.041. Epub 2023 Mar 22. PMID: 36958333.

Clark P. ‘Beethoven was black’: why the radical idea still has power today. The Guardian. 7 Sep 2020. https://www.theguardian.com/music/2020/sep/07/beethoven-was-black-why-the-radical-idea-still-has-power-today